FDA 510(k) Premarket Notification
The 510(k) is the most common FDA premarket submission pathway for medical devices. Under Section 510(k) of the FD&C Act and 21 CFR 807 Subpart E, a manufacturer must demonstrate that a new device is substantially equivalent (SE) to a legally marketed predicate device before introducing it to the U.S. market.
When a 510(k) is Required
A 510(k) submission is required before marketing a device that is classified into Class I with 510(k) requirement, Class II, or Class III (where no PMA is required) when:
- Introducing a device to the U.S. market for the first time
- Making a significant change or modification to the intended use of a legally marketed device
- Making a change or modification to a legally marketed device that could significantly affect its safety or effectiveness
Reference: 21 CFR 807.81(a); FDA Guidance "Deciding When to Submit a 510(k) for a Change to an Existing Device"
Types of 510(k) Submissions
| Type | When to Use | Key Characteristics |
|---|---|---|
| Traditional 510(k) | Default pathway when no recognized standard or special control guidance applies | Full comparison to predicate device; includes performance data, bench testing, and potentially clinical data |
| Special 510(k) | Modification to own legally marketed device where design controls can demonstrate SE | Relies on design control documentation; typically faster review (average 20 days); must use risk analysis to assess modification impact |
| Abbreviated 510(k) | Device conforms to recognized consensus standard(s) or FDA guidance document | Relies on conformance to recognized standards or special controls; summary report replaces detailed test data |
Reference: FDA Guidance "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications" (2014)
Substantial Equivalence
A device is substantially equivalent to a predicate device if it has the same intended use and either (1) the same technological characteristics, or (2) different technological characteristics but does not raise different questions of safety and effectiveness, and the information submitted demonstrates that the device is at least as safe and effective as the predicate.
Predicate Device Selection
- The predicate must be a legally marketed device (cleared through 510(k), pre-amendments, or reclassified via De Novo)
- Predicate must share the same intended use as the new device
- Multiple predicates can be used (split predicate approach) when different features are addressed by different predicates
- Search the FDA 510(k) database, product codes, and device classification database to identify candidate predicates
- Consider the predicate's labeling, indications for use, and technological characteristics
Reference: Section 513(i) of the FD&C Act; 21 CFR 807.87(f); 21 CFR 807.92(a)(3)
510(k) Submission Contents
The following table outlines the required and recommended sections for a Traditional 510(k) submission, per FDA guidance and 21 CFR 807.87.
| Section | Description | Reference |
|---|---|---|
| Cover Letter | Device name, product code, classification, contact information, type of 510(k) | 21 CFR 807.87 |
| Indications for Use | FDA Form 3881 with intended use, indications, prescription/OTC status | 21 CFR 807.87(e) |
| Device Description | Physical description, materials, design, principles of operation, accessories | 21 CFR 807.87(e) |
| Substantial Equivalence Comparison | Side-by-side comparison table: subject vs. predicate device features, specifications, intended use | 21 CFR 807.87(f) |
| Performance Data | Bench testing, biocompatibility (ISO 10993), electrical safety (IEC 60601), EMC testing, sterility validation | 21 CFR 807.87(g) |
| Biocompatibility | ISO 10993 biological evaluation per FDA guidance "Use of ISO 10993-1"; contact type, duration, and required endpoints | ISO 10993-1 |
| Software Documentation | Level of Concern, software description, hazard analysis, SRS, architecture, V&V testing per IEC 62304 | IEC 62304; FDA SW Guidance |
| Labeling | Proposed labels, IFU, packaging; must comply with 21 CFR 801 and UDI requirements (21 CFR 830) | 21 CFR 801; 21 CFR 830 |
| Sterilization | Sterilization method, validation data, shelf life, packaging integrity (if applicable) | ISO 11135; ISO 11137; ISO 11607 |
| Electromagnetic Compatibility | EMC testing per IEC 60601-1-2 for electronic devices; emissions and immunity data | IEC 60601-1-2 |
| Clinical Data | Clinical studies, literature review, or clinical experience data (if applicable to demonstrate SE) | 21 CFR 807.87(h) |
Review Process and Timeline
FDA's target review time for 510(k) submissions is 90 calendar days from receipt of a complete submission. The review process includes:
- Acceptance review (within 15 days): FDA determines if the submission is administratively complete
- Substantive review: Scientific review of SE determination, performance data, and labeling
- Additional information request: FDA may issue an AI letter requesting additional data (pauses the review clock)
- Decision: Substantially Equivalent (SE), Not Substantially Equivalent (NSE), or withdrawal
The FDA User Fee program (MDUFA) sets performance goals for review timelines. Actual review times vary by device complexity and submission quality.